Interim Analysis of a Post-authorisation Safety Study on the Long-Term Safety of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients with Primary Immunodeficiency Diseases in Europe

被引：0

作者：

Ellerbroek, P. M. ^{[1
]}

Van Paassen, P. ^{[2
]}

Hanitsch, L. ^{[3
]}

Plebani, A. ^{[4
,5
]}

Schmidt, R. E. ^{[6
]}

Van Hagen, P. M. ^{[7
]}

Wang, P. ^{[8
]}

Fielhauers, K. ^{[9
]}

Leibls, H. ^{[9
]}

Chavan, S. ^{[8
]}

Yel, L. ^{[10
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands

[2] Acad Ziekenhuis Maastricht, Maastricht, Netherlands

[3] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany

[4] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy

[5] ASST Spedali Civili Brescia, Brescia, Italy

[6] Hannover Med Sch, Klin Immunol & Rheumatol, Hannover, Germany

[7] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands

[8] Shire US Inc, Lexington, MA USA

[9] Baxalta Innovat GmbH, Vienna, Austria

[10] Baxalta US Inc, Cambridge, MA USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR2226

引用

页码：402 / 403

页数：2

共 50 条

[1] Interim analysis of a postauthorization safety study on long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in primary immunodeficiency disease in Europe
Ellerbroek, P. M.
van Paassen, P.
Hanitsch, L.
Plebani, A.
Schmidt, R. E.
van Hagen, P. M.
Wang, P.
Fielhauer, K.
Leibl, H.
Yel, L.
SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
[2] EUROPEAN POSTAUTHORIZATION SAFETY STUDY ON LONG-TERM HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN IN PRIMARY IMMUNODEFICIENCY DISEASES: INTERIM ANALYSIS
Ellerbroek, Pauline M.
van Paassen, Pieter
Hanitsch, Leif
Plebani, Alessandro
Schmidt, Reinhold E.
van Hagen, P. Martin
Wang, Ping
Fielhauer, Katharina
Leibl, Heinz
Chavan, Shailesh
Yel, Leman
MUSCLE & NERVE, 2020, 62 : S67 - S68
[3] Interim Analysis of the Global Post Authorization Safety Study of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Treatment in Patients With Primary Immunodeficiency Diseases
Rubinstein, Arye
Bridges, Tracy
McNeil, Donald
Tachdjian, Raffi
Wedner, H. James
Wasserman, Richard L.
Leibl, Heinz
Rabbat, Christopher
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (03) : 378 - 378
[4] Interim analysis of the global post authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency disease
Rubinstein, Arye
Bridges, Tracy
McNeil, Donald
Tachdjian, Raffi
Wedner, H. James
Wasserman, Richard L.
Leibl, Heinz
Rabbat, Christopher J.
Yel, Leman
ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (05) : 357 - 357
[5] Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study
Rubinstein, Arye
Bridges, Tracy A.
Wedner, H. James
McNeil, Donald
Wasserman, Richard L.
Tachdjian, Raffi
Stryk, Steven V.
Tarpay, Martha M.
Fielhauer, Katharina
Leibl, Heinz
Yel, Leman
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB117 - AB117
[6] POST-AUTHORIZATION SAFETY STUDY OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
Rubinstein, A.
Bridges, T.
McNeil, D.
Tachdjian, R.
Wedner, H.
Wasserman, R.
Leibl, H.
Rabbat, C.
Honigberg, R.
Yel, L.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S71 - S71
[7] INTERIM ANALYSIS OF THE GLOBAL POST AUTHORIZATION SAFETY STUDY OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE
Rubinstein, Arye
Bridges, Tracy
McNeil, Donald
Tachdjian, Raffi
Wedner, H. James
Wasserman, Richard
Leibl, Heinz
Rabbat, Christopher
Yel, Leman
MUSCLE & NERVE, 2019, 60 : S61 - S61
[8] Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
Ellerbroek, Pauline M.
Hanitsch, Leif G.
Witte, Torsten
Lougaris, Vassilios
van Hagen, P. Martin
Paassen, Pieter van
Chen, Jie
Fielhauer, Katharina
McCoy, Barbara
Nagy, Andras
Yel, Leman
IMMUNOTHERAPY, 2024, 16 (10) : 679 - 691
[9] Long-term Safety of Facilitated Subcutaneous Immunoglobulin Treatment in Patients With Primary Immunodeficiency Diseases: Interim Analysis from a Post-authorization Safety Study
Rubinstein, Arye
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB73 - AB73
[10] Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease
Patel, Niraj
Walter, Jolan
Wasserman, Richard
Rubinstein, Arye
Atkinson, T. Prescott
Shepherd, Meagan
Greco, Erin
Russo-Schwarzbaum, Sharon
Duff, Kimberly
Mccoy, Barbara
Chu, Liang-Hui
Li, Zhaoyang
Yel, Leman
CLINICAL IMMUNOLOGY, 2023, 250 : 148 - 149

← 1 2 3 4 5 →